Celtasquare Signs MOU with the Council for International Organizations of Medical Sciences (CIOMS) to Develop Korean Version of Pharmacovigilance Glossary

Artificial intelligence (AI)-based pharmacovigilance (PV) specialist company, Celtasquare (CEO Min-Kyung Shin), announced on the 28th that it will officially launch a project to develop the Korean version of the PV glossary in collaboration with the Council for International Organizations of Medical Sciences (CIOMS).

Celtasquare signed a business agreement with CIOMS to develop the Korean version of the "CIOMS Cumulative Pharmacovigilance Glossary, with a focus on Pharmacovigilance." CIOMS is an international non-governmental, non-profit organization jointly established by WHO and UNESCO in 1949, with a mission to advance public health through guidelines on ethics, medical product development, safety, and health research and policy.

CIOMS plays a leading role in the PV field, which involves activities to assess and monitor drug safety. Since the 1970s, it has continuously published guidelines that serve as the basis for international standards. Furthermore, since 2021, CIOMS has published and freely distributed the "CIOMS PV Glossary," which contains terms and definitions used in the PV field.

In response, Celtasquare expressed its commitment to contribute to the growth of the domestic pharmacovigilance market by developing the Korean version of the PV glossary with CIOMS. As Korea’s first AI-based PV specialist company, Celtasquare is driving changes across pharmacovigilance by enhancing efficiency and data accuracy through a platform applying advanced AI and IT technologies. The core strength lies in the experts at Celtasquare who possess practical PV experience throughout the entire product lifecycle, enabling sophisticated drug safety management.

This project will be directly conducted by Celtasquare’s PV experts in cooperation with CIOMS, and upon completion of the Korean version, it will be distributed online free of charge. Celtasquare expects this initiative to help deepen understanding of PV-related terms and concepts.

Min-Kyung Shin, CEO of Celtasquare, stated, "As the importance of drug safety management is increasingly emphasized, regulatory authorities are requiring pharmaceutical companies to conduct proactive risk management throughout the entire product lifecycle beyond simple post-marketing adverse event reporting, with the mandatory submission of DSURs being part of this." She added, "Although regulations are becoming stricter, there is still a severe shortage of PV professionals to comply with them, and existing personnel also need further learning and training to implement more advanced PV."

She continued, "Through this collaboration with a reputable organization that has long published international PV guidelines, we hope to maximize Celtasquare’s expertise and provide an opportunity that will benefit domestic PV professionals."